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Background Alternate-day administration of S-1 is thought to reduce toxicities. This phase II study 
evaluated S-1 on alternate days combined with bevacizumab as first-line treatment for elderly patients 
with metastatic colorectal cancer. 
Patients and Methods Eligible patients had histologically proven colorectal adenocarcinoma, 
measurable metastatic lesions, age ≥75 years, Eastern Cooperative Oncology Group performance status 
≤1, no previous chemotherapy, and refused oxaliplatin- or irinotecan-containing regimens. Patients 
received 40 mg, 50 mg, or 60 mg (body surface area ≤1.25 m2, >1.25 to ≤1.50 m2, or >1.50 m2, 
respectively) of S-1 twice orally on Sunday, Monday, Wednesday, and Friday every week. Bevacizumab 
(7.5 mg/kg) was administered every 3 weeks. The primary endpoint was progression-free survival. 
Results Of 54 enrolled patients, 50 patients were evaluated for efficacy and 53 for safety. The median age 
was 79 years (range, 75-88 years). The median progression-free survival was 8.1 months (95% 
confidence interval, 6.7-9.5 months). The median overall survival was 23.1 months (95% confidence 
interval, 17.4-28.8 months). The response rate was 44% (95% confidence interval, 30.2-57.8%), and the 
disease control rate was 88% (95% confidence interval, 79.0-97.0%). Grade 3 or higher hematologic, 



































































respectively. The most common grade 3 and 4 treatment-related adverse events were hypertension (11%), 
nausea (6%), fatigue (6%), anemia (6%), and proteinuria (6%). Only 6 patients discontinued treatment 
due to adverse events. 
Conclusion S-1 on alternate days combined with bevacizumab showed better tolerability and comparable 





































































Colorectal cancer (CRC) is a common cause of cancer-related death worldwide [1,2]. In Japan, more than 
70% of mortality occurs in patients over 75 years old. The proportion and number of elderly patients with 
metastatic CRC (mCRC) who are treated with chemotherapy is increasing [2]. 
The first-line standard treatment for patients with mCRC is doublet (fluoropyrimidine [FP] 
plus oxaliplatin or irinotecan) chemotherapy combined with a molecular targeted agent (bevacizumab, 
cetuximab, or panitumumab) [3-5]. However, elderly patients often cannot tolerate this combination 
chemotherapy because of emerging adverse events, comorbidity, and decreased organ function. 
Therefore, FP combined with bevacizumab has been recognized as a favorable treatment for elderly 
patients with mCRC [6-8]. 
 S-1, an oral FP, showed promising results in two phase II trials for chemo-naïve patients with 
mCRC [9,10]. The standard treatment schedule of S-1 was twice daily administration for 4 weeks 
followed by 2 weeks’ rest. To increase safety, S-1 on alternate days was studied as a new administration 
schedule, utilizing the difference in cell cycles between normal gastrointestinal epithelium and tumor 
cells: the normal cell cycle is approximately 0.5 to 1.5 days, whereas the tumor cell cycle ranges from 3 



































































cells [11-15]. In a retrospective study, this alternate-day S-1 schedule was studied in 92 patients with 
advanced gastric cancer. Grade 2 and higher non-hematologic toxicities were observed in only 3% of the 
patients, and the median time to treatment failure and median overall survival (OS) were 6 and 11 
months, respectively, which was similar to those in a previous study of the standard S-1 treatment 
schedule [16].  
 We herein report a phase II study of S-1 on alternate days combined with bevacizumab as a 
first-line treatment in elderly patients with mCRC. 
 
Material and Methods 
Study design 
This study was designed as a prospective, open-labeled, single-arm, multicenter phase II trial (J-SAVER: 
Joint study of S-1 on Alternate days combined with beVacizumab in Elderly patients with metastatic 
coloRectal cancer) by the nonprofit organization Tsukuba Cancer Clinical Trial Group and the Shikoku 
Gastrointestinal Oncology Study Group in Japan [17]. The study was conducted according to the 
Declaration of Helsinki/Tokyo and the Japanese Clinical Research Guidelines. The study protocol was 



































































by all patients before study entry. The study treatment was started within 14 days from the date of 
enrollment. The study protocol was registered at the University Hospital Medical Information Network, 
UMIN000010402, on April 2, 2013. 
 
Patients 
The main inclusion criteria were as follows: pathologically confirmed colorectal adenocarcinoma; age 
≥75 years; Eastern Cooperative Oncology Group performance status (ECOG PS) ≤1; no previous 
chemotherapy except for adjuvant chemotherapy with FP completed 6 months or more before enrollment; 
presence of measurable lesions as defined by the Response Evaluation Criteria in Solid Tumors 
(RECIST) version 1.1; and adequate bone marrow, hepatic, and renal function. The main exclusion 
criteria included inability to take oral medication, uncontrolled hypertension, previous radiation therapy 
over the pelvic cavity, urine protein ≥+2 with a stick kit for routine urinary analyses, and history of severe 
thrombosis. The details of the eligibility criteria have been previously reported [17]. RAS mutation was 
examined in paraffin-embedded tumor tissues at individual institutions using validated methods approved 







































































Patients received 40 mg (body surface area [BSA] ≤1.25 m2), 50 mg (BSA >1.25 to ≤1.50 m2), or 60 mg 
(BSA >1.50 m2) of S-1 orally, twice a day, on Sunday, Monday, Wednesday, and Friday every week. The 
protocol treatment was repeated until tumor progression, development of severe adverse events, or patient 
refusal. Bevacizumab was administered at 7.5 mg/kg every 3 weeks (Fig. 1). S-1 was postponed if the 
blood neutrophil count was < 1,000/mm3 or the platelet count was < 75,000/mm3. Re-initiation of S-1 
required non-hematological toxicities, including infection, diarrhea, oral mucositis, nausea, or vomiting, 
to be grade ≤1. S-1 was discontinued in cases of serum creatinine level ≥ 1.2 mg/dL, serum total bilirubin 
level ≥ 2.5 mg/dL, serum aspartic aminotransferase (AST) level or serum alanine aminotransferase (ALT) 
level > 100 IU (> 200 IU in patients with liver metastasis), and grade 2 or higher diarrhea, mucositis, 
nausea, or vomiting. S-1 was re-initiated at a reduced dose if patients recovered from these adverse 
events. The dosage of S-1 was reduced by 20% in patients who experienced a neutrophil count < 



































































4.0 mg/dL, serum AST or ALT level > 200 IU, or grade 3 or higher diarrhea, mucositis, nausea, or 
vomiting. In addition, dose reduction and treatment delay by physician’s determination were allowed, 
taking into account patient safety.  
 
Assessment 
Adverse events during treatment were assessed according to the Common Terminology Criteria for 
Adverse Events version 4.0. Blood tests included complete blood cell counts, liver and renal function 
tests, and tumor markers (carcinoembryonic antigen and carbohydrate antigen 19-9), and the urine test 
included a semi-quantitative protein test. Observation, assessment, and blood and urinary tests were 
performed every week until the second administration of bevacizumab, and every 3 weeks on the day of 
bevacizumab administration thereafter. Tumor assessments were performed according to RECIST version 
1.1. Computed tomography or magnetic resonance imaging was performed every 8 weeks for evaluation 
of tumors. The relative dose intensity (RDI) of S-1 and bevacizumab were calculated as the actual total 
dose divided by the pre-planned total dose during study treatment. A dedicated schedule calendar was 





































































The primary endpoint was progression-free survival (PFS). The secondary endpoints were safety, 
response rate, and OS. In a previous phase II study of standard S-1 monotherapy for patients with mCRC, 
the median PFS was 5.1 months [9,10]. The median PFS of 5-fluorouracil and leucovorin plus 
bevacizumab therapy was 3.7 months longer than that of 5-fluorouracil and leucovorin monotherapy in a 
randomized phase II study [6]. Therefore, we set the expected median PFS at 8.5 months and the 
minimum efficacy threshold at 5.0 months. The required sample size was calculated as 50 patients, with a 
two-sided type I error of 0.10 and a power of ≥ 80%. As post-hoc analyses, PFS and OS were evaluated 
according to RAS mutation status: exon 2 (codons 12 and 13), exon 3 (codons 59 and 61), and exon 4 
(codons 117 and 146) of KRAS and NRAS. PFS was defined as the time from enrollment to disease 
progression or death from any cause. OS was defined as the time from enrollment to death from any 
cause. The PFS and OS with 95% confidence interval (CI) were estimated using the Kaplan-Meier 
method. The response rate with 95% CI was calculated using normal approximation based on the best 
response by the investigator. P value of < .05 was considered to indicate statistical significance. All 






































































Fifty-four patients were enrolled from April 2013 to October 2016. Among them, 50 and 53 patients were 
evaluated for efficacy and safety, respectively. The flow chart of patient selection is shown in Fig. 2. 
 The median patient age was 79 years (range, 75-88 years) (Table 1). The ECOG PS was 0 in 
28 patients (56%) and 1 in 22 patients (44%). Primary tumors were located in the cecum, ascending 
colon, and transverse colon in 15 patients (30%) (right side), and in the descending colon, sigmoid colon, 
and rectum in 35 patients (70%) (left side). Half of the patients had one metastatic site. The tumor RAS 
mutation status was examined in 44 patients (21 wild-type and 23 mutant RAS).  
 
Efficacy 
The median follow-up times for PFS and OS were 34.5 and 44.9 months, respectively. PFS events 
occurred in 40 patients (80%). The median PFS was 8.1 months (95% CI, 6.7-9.5 months) (Fig. 3a). 
Thirty-nine patients (78%) died. The median OS was 23.1 months (95% CI, 17.4-28.8 months) (Fig. 3b). 
One patient showed complete response, and 21 had partial responses. The response rate was 44% (95% 



































































responses are shown in Fig. 4. Tumor shrinkage was observed in 37 patients (74%). Four patients showed 
100% tumor regression, but 2 patients with partial response had non-measurable lesions and 1 patient 
with stable disease had a new lesion when the measurable lesions had disappeared. 
 In post-hoc survival analyses according to RAS mutation status, the median PFS were 7.9 
months (95% CI, 7.1-8.7 months) for patients with wild-type RAS and 7.8 months (95% CI, 6.6-8.9 
months) for those with mutant RAS (P = 0.80). The median OS were 24.2 months (95% CI, 17.3-31.0 
months) for patients with wild-type RAS and 23.8 months (95% CI, 8.9-38.7 months) for those with 
mutant RAS (P = 0.80).  
 
Safety 
The adverse events are summarized in Table 2. Grade 3 or higher hematologic, non-hematologic, and 
bevacizumab-related adverse events were observed in 5 (9%), 6 (11%), and 13 (25%) patients, 
respectively. The most common grade 3 and 4 treatment-related adverse events were hypertension (11%), 
anemia (6%), nausea (6%), fatigue (6%), and proteinuria (6%). Treatment-related death caused by 



































































toxicities, and the dose of S-1 was reduced to 60% of the initial dose. He developed cerebral infarction 
after 13 doses of bevacizumab and died 12 months after the start of the study treatment. 
 The median duration of treatment was 7.8 months (range, 0.5-31.5 months). The median 
cumulative dose of S-1 was 13,060 mg (range, 280-54,250 mg) and that of bevacizumab was 3,980 mg 
(range, 270-24,910 mg). Seventeen patients (32%) required dose reduction or treatment delay of S-1, and 
14 patients (26%) required treatment delay of bevacizumab. The median RDI was 92% (range, 20-100%) 
for S-1 and 89% (range, 34-100%) for bevacizumab. The median RDI according to the original S-1 
treatment schedule was 79% (range, 18-84%). 
Subsequent treatments 
 Among the patients who received study treatment (n = 53), discontinuation of the study 
treatment was reported in 50 patients (94%), and the reason for discontinuation was disease progression 
in 40 patients (75%), adverse events in 6 patients (11%) (1 patient each: grade 2 anorexia, grade 2 
anorexia and fatigue, grade 3 anorexia, grade 3 wound dehiscence, grade 3 colonic perforation, and grade 
5 cerebral infarction), withdrawal of consent in 1 patient, and other in 3 patients (1 patient each: sepsis 
due to aspiration pneumonia, dementia, and unknown) (Table 3). After discontinuation of the study 



































































any chemotherapy, including oxaliplatin- and irinotecan-containing therapy (n = 14 and 8, respectively). 
In 22 patients who received oxaliplatin- or irinotecan- containing therapy, the median age was 78 years 
(range, 75-86 years), and 14 patients (64%) had an ECOG PS of 0. No complete response was observed, 
and 10 patients achieved partial response (45%). The incidences of grade 3 or higher hematologic-, non-
hematologic-, and bevacizumab-related toxicities were 5%, 9%, and 14%, respectively. The median RDIs 
were 95% (range, 46-98%) for S-1 and 93% (34-100%) for bevacizumab. 
 
Discussion  
We studied S-1 administration on alternate days combined with bevacizumab as first-line treatment for 
elderly (>75 years) patients with mCRC in a multicenter phase II trial, and showed modest activity and 
well-tolerated toxicities, while keeping dose intensities of S-1 and bevacizumab as high as approximately 
90%. 
 The main results reported in similar studies of elderly patients with mCRC are summarized in 
Table 4. The PFS in our study was comparable to those in previous studies of other FPs combined with 
bevacizumab [7,20-22]. The dose intensity of S-1 on alternate days corresponded with approximately 



































































79% of the standard dose in the present study. In general, FP plus bevacizumab has been reported to be 
well tolerated in elderly patients. However, the incidence of grade 3 or higher toxicities was reported as 
30% in two studies [7,23]. Even in other studies in which grade 3 or higher toxicities were observed in 
less than 10% of patients, treatment was discontinued due to relatively mild to moderate toxicities in 
approximately 30% of patients [20,22]. In contrast, the incidence of grade 3 or higher toxicities in our 
study was low, as expected, and only 11% of patients discontinued treatment due to toxicities. In 
addition, incidences of lacrimal disorder and skin disorder, including hand-foot skin reaction, were lower 
than those in previous studies in elderly patients [7,22]. This suggests that an alternate-day S-1 schedule 
had better tolerability than previously reported FP plus bevacizumab regimens. 
 Recently, two randomized phase II studies of alternate-day S-1 therapy were reported in 
advanced gastric and pancreatic cancers [24,25]. This regimen was inferior in efficacy to the standard 
daily S-1 regimen, although adverse events were mild. One plausible reason for these negative results is 
the insufficient anti-tumor activity of S-1 due to underdosing in the alternate-day schedule. Nevertheless, 
these results in advanced gastric and pancreatic cancer do not undermine our favorable results in elderly 
mCRC patients. These studies included younger patients who could have tolerated the standard daily S-1 



































































of FP was often adopted in previous studies for elderly patients with mCRC [6,20,21,23]. In a phase II 
study, aggressive dose modification of capecitabine plus bevacizumab provided rather favorable results in 
elderly mCRC patients [26]. In the FOCUS2 trial for elderly/frail patients in which FP alone or FP 
combined with oxaliplatin was started at a reduced dose, only 37% of patients could tolerated a dose 
increased to the standard level. In contrast, doublet regimens have been reported to demonstrate 
promising activity and tolerability in elderly patients with mCRC [23,27-30]. Although doublet regimens 
should be considered first for elderly patients, not all elderly patients can continue those treatments 
because of toxicities, and a considerable number of patients actually refuse them to avoid treatment-
related toxicities. Our regimen may be a good option as an introductory treatment for such patients. 
 Our study suggested that RAS mutation had no impact on PFS in patients administered FP 
plus bevacizumab, similar to the results of a previous report [31]. Anti-epidermal growth factor receptor 
(EGFR) antibody-containing therapy is recommended for mCRC patients with wild-type RAS, and 
bevacizumab-containing therapy is an optional treatment. In a previous report, the median PFS was 6.4 
months in elderly patients with wild-type KRAS and 8.4 months in those with wild-type KRAS/NRAS [32-



































































reported values. If elderly patients want to avoid anti-EGFR antibody-related skin toxicities, our regimen 
would be a good substitute.  
 Elderly patients are extremely diverse. Therefore, the present study had several limitations. 
The tolerability of chemotherapy for elderly patients is often associated with polypharmacy, comorbidity, 
renal function, psychological state, and family support [35,36]. We could not assess these important 
factors; however, they are very difficult to investigate in all clinical trials. Geriatric function assessment 
was lacking in our study. Various tools have been attempted for geriatric assessment in oncology trials, 
but a convenient, useful, and validated tool has not yet been established [35,36]. That the adherence rate 
of oral anti-cancer drugs is lower than that of intravenous anti-cancer drugs also needs to be considered 
[37]. In order to maintain the dose intensity of S-1 in this study, we asked the patients and their family 
members to record the day and dose of orally administered S-1 using a dedicated schedule calendar, and 
we checked the adherence. 
 In conclusion, alternate-day S-1 combined with bevacizumab was well tolerated and 
maintained activity in elderly patients (≥75 years old) with mCRC and might be recommended as an 
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Fig. 1 Treatment schedule. BSA, body-surface area. 
Fig. 2 Flow diagram indicating patient enrollment. 
Fig. 3 Kaplan-Meier curves of progression-free survival (a) and overall survival (b). The median 
progression-free survival was 8.1 months (95% CI, 6.7-9.5). The median overall survival was 23.1 
months (95% CI, 17.4-28.8). CI, confidence interval. 
Fig. 4 Waterfall plots according to the best response. CR, complete response; PD, progressive disease; 


































































Table 1 Patient characteristics  
Characteristics n = 50 % 
Age (years)  
  Median (range) 79 (75-88) 
Gender   
  Male 25 50 
  Female 25 50 
ECOG performance status   
  0 28 56 
  1 22 44 
Histology   
  Well differentiated adenocarcinoma 10 20 
  Moderate differentiated adenocarcinoma 35 70 
  Poorly differentiated adenocarcinoma  2  4 
  Mucinous adenocarcinoma  3  6 
Primary tumor site   
  Cecum/ascending colon/transverse colon 15 30 
  Descending colon/sigmoid colon/rectum 35 70 
Metastasis   
  Synchronous 33 66 
  Metachronous 17 34 
Primary therapy   
  Resection of primary tumor 39 78 
  Adjuvant chemotherapy  5 10 
Metastatic organ site   
  Liver 28 56 
  Lung 19 38 
  Peritoneum 15 30 
  Lymph node 11 22 
  Others 12 24 
Number of metastatic organ site   
  1 26 52 
  2 17 34 
  ≥3  7 14 
RAS status   
  KRAS exon 2† wild-type  9 18 
  KRAS/NRAS‡ wild-type 12 24 
Table 1 Patient characteristics Click here to access/download;Table;Table 1 Patient
characteristics_JSAVER.docx
  KRAS/NRAS‡ mutant-type 23 46 
  Unkown  6 12 
†codon 12 and 13. ‡exon 2 (codon 12 and 13), exon 3 (codon 59 and 61), and 
exon 4 (117 and 146) of KRAS and NRAS 
ECOG PS Eastern Cooperative Oncology Group Performance Status 
 
Table 2 Treatment-related adverse events 
Toxicities 
Toxicity grade† (n = 53) 
0 1 2 3 4 Any (%) ≧3 (%) 
Hematologic        
  Any 21 15 12 5 0 60 9 
  Neutropenia 43 3 5 2 0 19 4 
  Anemia 25 14 7 3 0 53 6 
  Thrombocytopenia 29 10 4 0 0 45 0 
Non-hematologic        
  Any 14 17 16 6 0 74 11 
  Oral mucositis 39 10 4 0 0 26 0 
  Nausea 34 10 6 3 - 36 6 
  Vomiting 47 3 3 0 0 11 0 
  Diarrhea 42 6 3 2 0 21 4 
  Fatigue 31 14 5 3 - 42 6 
  Anorexia 44 3 5 1 0 17 2 
  Lacrimal disorder 47 4 2 0 0 11 0 
  Skin disorder 38 13 2 0 0 28 0 
  Febrile neutropenia 53 - - 0 0 0 0 
Bevacizumab-related        
  Any 15 11 14 11 2‡ 72 25 
  Hypertension 33 6 8 6 0 38 11 
  Bleeding 37 13 1 2 0 30 4 
  Proteinuria 27 8 15 3 0 49 6 
  Thrombosis 51 0 1 0 1‡ 4 2 
  Wound dehiscence 52 0 0 1 0 2 2 
  Colonic perforation 52 0 0 0 1 2 2 
-: Grade is not available 
†Toxicity grade was done according to the National Cancer Institute Common 
Terminology Criteria version 4.0 
Table 2 Adverse events Click here to access/download;Table;Table 2 adverse
events_JSAVER.docx
‡Treatment related death was observed in one patient 
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 1 
Table 3 Subsequent treatment 
 (n = 53) % 
Study treatment continued 3 6 
Study treatment discontinued 50 94 
Best supportive care  14 26 
Any chemotherapies 32 60 
      Oxaliplatin-containing 14 26 
      Irinotecan-containing 8 15 
      Fluoropyrimidine alone or with bevacizumab 7 13 
      Anti-EGFR antibody alone 1 2 
      Trifluridine/tipiracil 2 4 
      Other 1 2 
Radiotherapy  2 4 
Treatment-related death 1 2 
EGFR epidermal growth factor receptor.   
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Table 4 Summary of studies of oral fluoropyrimidine with bevacizumab as first-line therapy for elderly patients with metastatic colorectal cancer 
 J-BLUE18 Osaka19 BASIC20 AVEX7 Present study 
Trial phase II II II III II 
FP combined with bevacizumab UFT/LV UFT/LV S-1 Capecitabine Alternate-day S-1   
Schedule of FP 300 mg/m2/day for 
3 weeks on,1 week 
off 
300 mg/m2/day for 
3 weeks on, 1 week 
off 
80 mg/m2/day 
for 4 weeks on, 
2 weeks off 
2,000 mg/m2/day 
for 2 weeks on, 1 
week off 
80 mg/m2/day on 
Sun, Mon, Wed, 
and Fri 
Number of patients†  52 40 56 134 50 
Age (years), median (range) 80 (75-87) 81 (75-90) 75 (66-85) 76 (70-87) 79 (75-88) 
ECOG PS ≥1, % 27 13 50 48 44 
Median PFS, month 8.2 8.9 9.9 9.1 8.1 
Median OS, month 23.0 21.7 25.0 20.7 21.0 
Any AEs grade ≥3, % 29 NR NR 40 36 
Discontinuation due to AEs‡, % 25 NR 32 17 11 
†Efficacy analysis population 
‡Of the number of patients who received study treatment 
AEs adverse events ECOG PS Eastern Cooperative Oncology Group Performance Status FP fluoropyrimidine LV oral leucovorin NR not 
reported OS overall survival PFS progression-free survival UFT Uracil-Tegafur 
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Fig. 2 Flow diagram indicating patient enrollment Click here to access/download;Figure;Fig 2 Flow diagram
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Fig. 3a Kaplan-Meier curves of progression-free survival Click here to access/download;Figure;Fig 3a_PFS.tiff
Fig 3b Kaplan-Meier curves of overall survival Click here to access/download;Figure;Fig 3b_OS.tiff
Fig 4 Waterfall plots to the best response Click here to access/download;Figure;Fig 4 waterfall plots to the best response.tiff
